Lupus Nephritis Market Report 2026

Lupus Nephritis Market Overview

• Lupus Nephritis market size has reached to $2.08 billion in 2025 • Expected to grow to $2.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Rising Genetic Predisposition Driving The Growth Of The Market Due To Its Role In Autoimmune Disease Development • Market Trend: Advancements In Second-Generation Calcineurin Inhibitors For Enhanced Lupus Nephritis Treatment • Asia-Pacific was the largest region in 2025.

What Is Covered Under Lupus Nephritis Market?

Lupus nephritis is a serious kidney condition caused by systemic lupus erythematosus (SLE), an autoimmune disease in which the body's immune system mistakenly attacks healthy tissues, including the kidneys. This inflammation can lead to kidney damage, impaired function, and, if left untreated, potentially kidney failure, making early diagnosis and treatment crucial for managing the disease. The main stages of lupus nephritis are class 1, class 2, class 3, and others. Class 1 refers to a stage of lupus nephritis with minimal kidney damage, where kidney function remains stable, and symptoms are not typically noticeable. Treatment focuses on preventing further progression of the disease. Various drug classes include immunosuppressive drugs, corticosteroids, biological agents, and antimalarial drugs, which are administered through oral, parenteral, and other routes. Treatment is distributed through hospital pharmacies, retail pharmacies, and online pharmacies by end-users such as hospitals, specialty clinics, and others.

What Is The Lupus Nephritis Market Growth Forecast?

The lupus nephritis market size is expected to see strong growth in the next few years. It will grow to $2.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising investment in biologic drug development, increasing focus on early intervention to prevent kidney failure, growing adoption of combination therapy regimens, expansion of specialty nephrology clinics, increasing healthcare spending on autoimmune disease management. Major trends in the forecast period include rising focus on early diagnosis and disease monitoring, growing adoption of immunosuppressive and biologic therapies, increasing emphasis on personalized treatment approaches, expansion of long-term disease management strategies, rising awareness of autoimmune kidney complications.

Global Lupus Nephritis Market Segmentation

1) By Stage: Class 1, Class 2, Class 3, Other Stages 2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs 3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis 2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition 3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation 4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

What Is The Driver Of The Lupus Nephritis Market?

The increasing prevalence of genetic predisposition is expected to propel the growth of the lupus nephritis market going forward. Genetic predisposition refers to an individual's inherited genetic traits that increase their likelihood of developing certain diseases or conditions. The increasing prevalence of genetic predisposition is due to factors such as inheritance, environmental influences, and mutations in specific genes. The increasing prevalence of genetic predisposition plays a significant role in the development of lupus nephritis, emphasizing the impact of inherited genetic factors in autoimmune diseases, particularly those affecting kidney function. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, the UK CF Registry recorded 11,148 registered patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% increase in individuals with cystic fibrosis (CF). Therefore, the increasing prevalence of genetic predisposition is driving the growth of the lupus nephritis industry.

Key Players In The Global Lupus Nephritis Market

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

Global Lupus Nephritis Market Trends and Insights

Major companies operating in the lupus nephritis market are focusing on developing advanced second-generation calcineurin inhibitors to enhance treatment efficacy and improve long-term kidney outcomes for patients. Second-generation calcineurin inhibitors are used in lupus nephritis to reduce inflammation and prevent kidney damage by modulating immune responses. For instance, in September 2024, Aurinia Pharmaceuticals Inc., a Canada-based commercial-stage biopharmaceutical company, announced that the Japanese Ministry of Health, Labour, and Welfare approved LUPKYNIS (voclosporin) for the treatment of lupus nephritis. This approval allows voclosporin to be used in combination with mycophenolate mofetil (MMF), based on data from the AURORA Clinical Program, which demonstrated its safety and efficacy. The approval marks a significant milestone in expanding treatment options for lupus nephritis patients in Japan, improving disease management and outcomes.

What Are Latest Mergers And Acquisitions In The Lupus Nephritis Market?

In March 2024, Lupus Therapeutics, a US-based Lupus Research Alliance affiliate clinical research partner, partnered with Artiva Biotherapeutics Inc. to support the clinical trial for lupus nephritis. With this collaboration, Lupus Therapeutics aims to conduct a Phase 1 trial to evaluate Artiva's AlloNK therapy with anti-CD20 antibodies for patients with active lupus nephritis, assessing its safety and effectiveness as a treatment for this serious kidney complication. Artiva Biotherapeutics is a US-based biotechnology company that provides treatment for lupus nephritis.

Regional Outlook

Asia-Pacific was the largest region in the lupus nephritis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lupus Nephritis Market?

The lupus nephritis market consists of revenues earned by entities by providing services such as dialysis services, diagnostic testing, renal care services, and home healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus nephritis market also consists of sales of medical devices, diagnostic products, and renal replacement products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lupus Nephritis Market Report 2026?

The lupus nephritis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lupus nephritis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.